Award
National Institute of Allergy and Infectious Diseases 2U19AI095219-16
Pathophysiologic and Therapeutic Mechanisms of Aspirin Exacerbated Respiratory Disease
Recipient
Brigham and Women's Hospital
Award Amount
$1,530,450.00
Ceiling
$1,530,450.00
Awarded
May 26, 2026
Identifier
2U19AI095219-16
NIH grant awarded to Brigham and Women's Hospital to study mechanisms and therapies for aspirin-exacerbated respiratory disease, focusing on immune and cellular pathways.
Description
This grant continues to focus on the mechanistic basis of respiratory tract type 2 immunopathology (T2I), particularly in aspirin-exacerbated respiratory disease (AERD). It aims to identify cellular and molecular drivers of disease severity, including mast cell proliferation, epithelial cell dysfunction, and mTOR signaling pathways, with the goal of developing targeted therapies.